Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals

What Was Tested

Researchers studied Kisspeptin-10 in this randomized controlled trial publication.

To determine the endocrine profile of MVT-602 in the follicular phase of healthy premenopausal women (phase-1 trial), and after minimal ovarian stimulation to more closely reflect the endocrine milieu encountered during MAR (phase-2a trial).

Why It Was Studied

Kisspeptin is an essential regulator of hypothalamic gonadotropin-releasing hormone release and is required for physiological ovulation.

Native kisspeptin-54 can induce oocyte maturation during in vitro fertilization treatment, including in women who are at high risk of ovarian hyperstimulation syndrome.

Who Took Part

PubMed indexes the participants as teenagers, young adults and adults, women only.

Healthy women aged 18-35 years, either without (phase-1; n = 24), or with ovarian stimulation (phase-2a; n = 75).

How the Study Was Run

The design is described as randomized, placebo-controlled and parallel-group.

Random assignment meant chance, not the researchers, decided who got Kisspeptin-10 and who got the comparison, which limits bias.

Some participants received a placebo instead of Kisspeptin-10, giving a reference point.

The Kisspeptin-10 group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Fertilization in Vitro, Gonadotropin-Releasing Hormone, Kisspeptins, Luteinizing Hormone, Ovulation Induction and Triptorelin Pamoate.

Author keywords: MVT-602, fertility and kisspeptin receptor agonist.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and parallel-group study of Kisspeptin-10.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Fertility and sterility), a journal based in United States.

More context: the Kisspeptin-10 compound page, all human trials.